Are Medical Stocks Lagging BrightSpring Health Services, Inc. ( BTSG ) This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Arcutis Biotherapeutics, Inc. ( ARQT ) Recently Broke Out Above the 20-Day Moving Average
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® ( roflumilast ) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to ...
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Arcutis Biotherapeutics Inc's ( NYSE:ARQT ) short interest as a percent of float has fallen 8.03% since its last report. According to exchange reported data, there are now 13.48 million shares sold short, which is 13.52% of all regular shares that are available for trading.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Palvella's recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies ...
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised
NVAX exceeds third-quarter expectations, boosted by a Sanofi milestone payment. It lifts its 2025 sales outlook.
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised
Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.
TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues. Stock falls.
Wall Street Analysts Believe Arcutis Biotherapeutics ( ARQT ) Could Rally 26.53%: Here's is How to Trade
The consensus price target hints at a 26.5% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised
TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® ( roflumilast ) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis ...
Arcutis Biotherapeutics, Inc. ( ARQT ) Hits Fresh High: Is There Still Room to Run?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Makes Arcutis Biotherapeutics ( ARQT ) a New Strong Buy Stock
Arcutis Biotherapeutics (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Grifols ( GRFS ) Stock Outpacing Its Medical Peers This Year?
Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign ...
Arcutis Launches ZORYVE® ( roflumilast ) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5 - Arcutis Biotherapeutics ( NASDAQ:ARQT )
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can be used anywhere on the body for any duration and is not a steroid
Arcutis Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, October 28, 2025 at 10:30 a.m. ETChief Executive Officer - Todd WatanabeContinue reading ...
Crude Oil Falls Over 2%; PayPal Shares Spike Higher - Alexandria Real Estate ( NYSE:ARE ) , Arcutis Biotherapeutics ( NASDAQ:ARQT )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Tuesday. The Dow traded up 0.39% to 47,731.04 while the NASDAQ rose 0.42% to 23,736.30. The S&P 500 also rose, gaining, 0.07% to 6,879.97. Information technology shares jumped by 0.7% on Tuesday.
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today
Arcutis Biotherapeutics had an excellent update for investors and its future looks bright.
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Agilysys ( NASDAQ:AGYS )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Tuesday. Shares of Wayfair Inc ( NYSE:W ) rose sharply during Tuesday's session following better-than-expected third-quarter results.
Arcutis Biotherapeutics, Inc. ( ARQT ) Q3 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +160.00% and +14.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® ( roflumilast ) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that new data demonstrating ZORYVE® ( ...
Arcutis Biotherapeutics, Inc. ( ARQT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals ( TARS ) Moves 10.9% Higher: Will This Strength Last?
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( NASDAQ:ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,500 restricted stock units ...
Arcutis Biotherapeutics, Inc. ( ARQT ) Hit a 52 Week High, Can the Run Continue?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Arcutis Biotherapeutics ( ARQT ) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Here's Why Arcutis Biotherapeutics, Inc. ( ARQT ) is a Great Momentum Stock to Buy
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arcutis To Present Multiple New ZORYVE® ( roflumilast ) Data Analyses at European Academy of Dermatology and Venereology Congress
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress ...
Are Medical Stocks Lagging AxoGen ( AXGN ) This Year?
Here is how AxoGen (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
WESTLAKE VILLAGE, Calif., Sept. 05, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ( Nasdaq: ARQT ) , a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 35,500 restricted stock ...
Arcutis Submits Supplemental New Drug Application for ZORYVE® ( roflumilast ) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children ...
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies ...
Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Palvella Therapeutics ( NASDAQ:PVLA )
Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies
Does Arcutis Biotherapeutics ( ARQT ) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Top 5 Biotech Stocks With Strong Momentum - ADC Therapeutics ( NYSE:ADCT ) , Arcutis Biotherapeutics ( NASDAQ:ARQT )
Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains.
Is Arcutis Biotherapeutics ( ARQT ) Stock Outpacing Its Medical Peers This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics ( ARQT ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
Are Medical Stocks Lagging Arcutis Biotherapeutics ( ARQT ) This Year?
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT )
WESTLAKE VILLAGE, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Arcutis Biotherapeutics, Inc. ARQT, a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 21,000 restricted stock units of Arcutis' ...
Arcutis ( ARQT ) Q2 Revenue Soars 164%
Arcutis Biotherapeutics ( NASDAQ:ARQT ) , a dermatology-focused pharmaceutical company, reported earnings results on August 6, 2025. Highlights included strong revenue growth and improved earnings, significantly outperforming Wall Street expectations, with GAAP revenue of $81.5 million and GAAP ...
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q2 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcutis Biotherapeutics, Inc. ( ARQT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
